Journal
CHEST
Volume 140, Issue 3, Pages 706-714Publisher
ELSEVIER
DOI: 10.1378/chest.10-1944
Keywords
-
Categories
Funding
- Sanofi-Aventis
- Medicines Company
- Procter Gamble
- Scios Inc
- GlaxoSmithKline
- Bayer
- Blue Cross Blue Shield of Michigan
- Core and Mardigian Foundation
- Bristol-Meyers Squibb
- Bayer HealthCare
- Boehringer-Ingelheim
- Pfizer
- Eisai Co Ltd
Ask authors/readers for more resources
Background: Acutely ill hospitalized medical patients are at risk for VTE. We assessed the incidence of VTE in the observational International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) study and derived VTE risk assessment scores at admission and associative VTE scores during hospitalization. Methods: Data from 15,156 medical patients were analyzed to determine the cumulative incidence of clinically observed VTE over 3 months after admission. Multiple regression analysis identified factors associated with VTE risk. Results: Of the 184 patients who developed symptomatic VTE, 76 had pulmonary embolism, and 67 had lower-extremity DVT. Cumulative VTE incidence was 1.0%; 45% of events occurred after discharge. Factors independently associated with VTE were previous VTE, known thrombophilia, cancer, age >60 years, lower-limb paralysis, immobilization >= 7 days, and admission to an ICU or coronary care unit (first four were available at admission). Points were assigned to each factor identified to give a total risk score for each patient. At admission, 67% of patients had a score >= 1. During hospitalization, 31% had a score >= 2; for a score of 2 or 3, observed VTE risk was 1.5% vs 5.7% for a score >= 4. Observed and predicted rates were similar for both models (C statistic, 0.65 and 0.69, respectively). During hospitalization, a score >= 2 was associated with higher overall and VTE-related mortality. Conclusions: Weighted VTE risk scores derived from four clinical risk factors at hospital admission can predict VTE risk in acutely ill hospitalized medical patients. Scores derived from seven clinical factors during hospitalization may help us to further understand symptomatic VTE risk. These scores require external validation. CHEST 2011; 140(3):706-714
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available